Psilocybin and its direct precursor baeocystin are indole alkaloids of psychotropic Psilocybe mushrooms. The pharmaceutical interesti np silocybin as at reatment optiona gainst depression and anxiety is currently being investigated in advanced clinicalt rials. Here, we reportabiocatalytic route to synthesize 6-methylated psilocybin and baeocystin from 4-hydroxy-6methyl-l-tryptophan, which was decarboxylated and phosphorylated by the Psilocybec ubensis biosynthesis enzymes PsiD and PsiK. N-Methylation was catalyzed by PsiM. We further present an in silico structural model of PsiM that revealed aw ell-conserved SAM-binding core along with peripheraln onconserved elements that likely govern substrate preferences.The indole nucleus is ac ommon motif with bioactiven atural products that is, in numerous instances, modified duringb iosynthesis. Modifications include, for example, 7-chlorination in the case of rebeccamycin, prenyl transfer to various positions to make asterriquinones, or hydroxylation at C-5 and C-6 of serotonin and amanitins,r espectively.R eserpine, ibogaine, and harmaline are methoxy-substituted att hesec arbons. Dissimilar from the above positionsa nd substituents, psilocybin( 1, Scheme 1) features aunique 4-phosphoryloxy group.Compound 1 is the principal metabolite of Psilocybe carpophores ("magic mushrooms"), whereas baeocystin (2)a nd norbaeocystin (3), the immediate metabolic precursors, are present in minor quantities. [1] The dephosphorylated analogue of 1, psilocin (4), represents the pharmacologically active, that is, psychotropic compound as it is ap artial agonist at the human 5HT 2A receptor. [2] The pharmaceutical value of 1 in the treat-ment of end-of-life anxiety and therapy refractory depression has been documentedi nv ariousa dvanced clinicalt rials. [3] Syntheses of 1 congeners date back to the late 1950s. Following the discovery of 1 by Albert Hofmann and co-workers, various series of derivatives were synthesized,w hich also contained the 6-phosphoryloxy and 6-hydroxy isomerso f1 and 4,a long with a6 -methylated, side-chain-alkylated tryptamine. [4] Subsequent efforts were made to install bromine or af ormyl group at C-5-or C-7, vary the substituents at the w-N-atom of 4,o r add various substituentst ot he aromatic ring of N,N-dimethyltryptamine (5), to produce its 6-and 7-methyl analogues, among others. [5] Despite theser esultsa nd despite the synthesis of 2-methyl derivatives of 5 and N,N-diethyltryptamine, [6] none of the previouse fforts, using synthetic chemistry,h ad focused on introducing am ethyl substituent to the indole of 1 or 2.We report the in vitro synthesis of 6-methylpsilocybin (6, Scheme1)a nd, as main products,i ts immediate precursors 6methylnorbaeocystin (7)a nd 6-methylbaeocystin (8). We address the previous lack of ring-methylated 1 analogues and simultaneously provide am odel of the PsiM structure for insight into the origin of its methylating activity on 3 and 7.W ei dentified al oop structure as criticalf or methyl acceptors ubstrate selectivity.C oncu...